Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Geron Corp (GERN)
Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,831,561
  • Shares Outstanding, K 508,767
  • Annual Sales, $ 600 K
  • Annual Income, $ -141,900 K
  • 60-Month Beta 0.90
  • Price/Sales 2,885.29
  • Price/Cash Flow N/A
  • Price/Book 5.10
Trade GERN with:

Options Overview Details

View History
  • Implied Volatility 76.67% ( +4.12%)
  • Historical Volatility 53.89%
  • IV Percentile 34%
  • IV Rank 12.92%
  • IV High 324.34% on 11/09/22
  • IV Low 39.91% on 03/24/23
  • Put/Call Vol Ratio 0.41
  • Today's Volume 5,134
  • Volume Avg (30-Day) 3,485
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 90,133
  • Open Int (30-Day) 72,251

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.08
  • Number of Estimates 3
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.48 +45.16%
on 05/03/23
3.66 -1.77%
on 06/02/23
+1.12 (+45.16%)
since 05/02/23
3-Month
1.95 +84.62%
on 04/14/23
3.66 -1.77%
on 06/02/23
+0.80 (+28.57%)
since 03/02/23
52-Week
1.18 +205.08%
on 06/16/22
3.84 -6.25%
on 01/04/23
+2.27 (+170.68%)
since 06/02/22

Most Recent Stories

More News
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June

/PRNewswire/ -- USA News Group - With this year's Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days away, there's...

ONC.TO : 2.28 (+1.79%)
ONCY : 1.7200 (+3.61%)
JAZZ : 128.34 (-0.60%)
GERN : 3.60 (+6.51%)
INAB : 3.15 (+2.94%)
VCYT : 26.72 (+2.02%)
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END

ONCY : 1.7200 (+3.61%)
ONC.TO : 2.28 (+1.79%)
JAZZ : 128.34 (-0.60%)
GERN : 3.60 (+6.51%)
INAB : 3.15 (+2.94%)
VCYT : 26.72 (+2.02%)
Significant Oncology Results Set to be Delivered as Oral Presentations at ASCO 2023

USA News Group – With this year’s Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days away, there’s plenty of anticipation for updates on some of the biggest...

ONCY : 1.7200 (+3.61%)
ONC.TO : 2.28 (+1.79%)
JAZZ : 128.34 (-0.60%)
GERN : 3.60 (+6.51%)
INAB : 3.15 (+2.94%)
VCYT : 26.72 (+2.02%)
Geron (GERN) Q1 2023 Earnings Call Transcript

GERN earnings call for the period ending March 31, 2023.

GERN : 3.60 (+6.51%)
Geron (GERN) Reports Q1 Loss, Misses Revenue Estimates

Geron (GERN) delivered earnings and revenue surprises of 22.22% and 85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

GERN : 3.60 (+6.51%)
LVTX : 2.60 (+36.84%)
Geron: Q1 Earnings Snapshot

Geron: Q1 Earnings Snapshot

GERN : 3.60 (+6.51%)
ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 55.56% and 8.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

ITOS : 15.53 (-2.02%)
GERN : 3.60 (+6.51%)
Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates

Seer, Inc. (SEER) delivered earnings and revenue surprises of -2.70% and 1.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

SEER : 4.07 (+3.30%)
GERN : 3.60 (+6.51%)
Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.29% and 163.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CYTK : 38.63 (+1.77%)
GERN : 3.60 (+6.51%)
Geron to Announce First Quarter 2023 Financial Results on May 11, 2023

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023 at 8:00 a.m. Eastern...

GERN : 3.60 (+6.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 4.00
2nd Resistance Point 3.83
1st Resistance Point 3.72
Last Price 3.60
1st Support Level 3.43
2nd Support Level 3.26
3rd Support Level 3.15

See More

52-Week High 3.84
Last Price 3.60
Fibonacci 61.8% 2.82
Fibonacci 50% 2.51
Fibonacci 38.2% 2.20
52-Week Low 1.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar